10月31日,Bio Rad实验室(Bio Rad Laboratories Inc)股价盘中大涨7.73%,报收于349.76美元/股,引发市场广泛关注。据报道,公司最新一季度营收和净利润数据表现亮眼,且机构分析师对其长期增长前景持乐观看法。
消息面上,Bio Rad上一季度实现营业收入6.38亿美元,环比增长5.2%,超出预期。虽然净利润出现亏损,但毛利率保持在较高水平。公司在生命科学和临床诊断领域均占有一定市场份额,尤其是数字PCR技术处于领先地位。
多家机构调高了对Bio Rad的评级和目标价。加拿大皇家银行将其目标价上调至469美元,看好公司持续的创新实力和国际化布局。分析人士认为,Bio Rad具备全面的产品线和创新管线,有望持续受益于生命科学和医疗健康市场的快速增长。此外,公司与赛多利斯的战略合作也有望带来协同效应,推动长期发展前景向好。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.